Categories
- Aesthetic Medicine
- Aesthetic Surgery
- Ai
- ALS Treatment
- Anatomy
- Artificial General Intelligence
- Artificial Intelligence
- Artificial Super Intelligence
- Batten Disease Treatment
- BioEngineering
- BioInformatics
- Biology
- Biotechnology
- Bitcoin
- Brain Injury Treatment
- Cardiac Nursing
- Cardiac Regeneration
- Cardiac Remodeling
- Cardiac Rhythm Abnormalities
- Cardiac Surgery
- Cardiology
- Cardiomyopathies
- Cardiovascular Pharmacology
- Cell Medicine
- Cell Therapy
- Cerebral Palsy
- Cerebral Palsy Treatment
- Cheap Pharmacy
- Chemistry
- Clinical Cardiology
- Coronary Heart Diseases
- Cryptocurrency
- DNA
- Drug Dependency
- Drug Side Effects
- Drugs
- Eczema
- Elon Musk
- Embryology
- Erectile Dysfunction
- FDA Stem Cell Trials
- Femtomedicine
- Future Medicine
- Gene Medicine
- Gene Therapy
- Gene Therapy Trials
- Genetic Engineering
- Genetic Therapy
- Genetics
- Germ Line Engineering
- Heart Diseases
- HGH
- Hgh Injections
- Hormone Replacement Therapy
- Human Genetics
- Human Growth Hormone
- Human Immortality
- Hyperbaric Medicine
- Hypertension
- Hypothalamus
- Impotency
- Internet Pharmacy
- Interventional Cardiology
- IVF Treatment
- Lyme Disease
- Male Sexual Dysfunction
- Mars Colony
- Medical Business
- Medical School
- Medical Technology
- Medicine
- Mental Health
- Mesenchymal Stem Cells
- Micropenia
- Molecular Cardiology
- MS Treatment
- Muscular Dystrophy Treatment
- Myocardial Infarction
- Nanotechnology
- Online Pharmacy
- Oral Health
- Parkinson's Treatment
- Pediatric Cardiology
- Penis Enlargement
- Pet Stem Cell Therapy
- Pharmacy
- Picomedicine
- Premature Ejaculation
- Prescriptions
- Retinitis Pigmentosa
- Sermorelin
- Singularity
- Sleep
- Spacex
- Spinal Cord Injury Treatment
- Stem Cell Clinical Trials
- Stem Cell Experiments
- Stem Cell Human Trials
- Stem Cell Injections
- Stem Cell Research
- Stem Cell Transplant
- Stem Cell Treatments
- Testosterone
- Ulcerative Colitis
- Uncategorized
- Vascular Biology
- Ventricular Remodeling
- Wholesale Pharmacy
Archives
Category Archives: Ulcerative Colitis
Crohn’s and Colitis Canada Awards Over $1.2 Million to New Research Projects through Annual Grant Competitions – GlobeNewswire
Posted: Published on December 18th, 2020
December 15, 2020 11:00 ET | Source: Crohn's and Colitis Canada multilang-release TORONTO, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Crohns and Colitis Canada is delighted to award over $1.2 million in new grants through its Grants-in-Aid of Research and Innovations in IBD Research grant programs. With funds distributed among five principal investigators and their teams, the grants will support novel research projects focused on Crohns disease and ulcerative colitis, the two main forms of inflammatory bowel disease (IBD). Continue reading
Posted in Ulcerative Colitis
Comments Off on Crohn’s and Colitis Canada Awards Over $1.2 Million to New Research Projects through Annual Grant Competitions – GlobeNewswire
Opinion | You don’t have to be staggered by Crohn’s diagnosis – TheSpec.com
Posted: Published on December 18th, 2020
When she was nine years old, Emma Haist started having bad cramps and losing weight. She would come home from school and lie on the couch, sleeping through dinner until the next morning. At first, her family doctor thought she might be allergic to dairy or glucose Continue reading
Posted in Ulcerative Colitis
Comments Off on Opinion | You don’t have to be staggered by Crohn’s diagnosis – TheSpec.com
Prometheus Biosciences Announces FDA Acceptance of IND Application for PRA023 and Commences Dosing in Phase 1a Clinical Study – BioSpace
Posted: Published on December 18th, 2020
SAN DIEGO, Dec. 15, 2020 /PRNewswire/ --Prometheus Biosciences, Inc. ("Prometheus"), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the diagnosis and treatment of inflammatory bowel disease (IBD), today announced FDA acceptance of its Investigational New Drug Application (IND) for PRA023 and that dosing has commenced in a Phase 1a clinical study in normal healthy volunteers. Continue reading
Posted in Ulcerative Colitis
Comments Off on Prometheus Biosciences Announces FDA Acceptance of IND Application for PRA023 and Commences Dosing in Phase 1a Clinical Study – BioSpace
I Have a Chronic Illness. Here’s Why I Hate New Year’s Resolutions – Healthline
Posted: Published on December 18th, 2020
Written by Hattie Gladwell on December 15, 2020 Fact checked by Jennifer Chesak We need to stop starting every new year by setting these unreachable standards for ourselves. Each year, my social media feeds are filled with New Years resolutions. Continue reading
Posted in Ulcerative Colitis
Comments Off on I Have a Chronic Illness. Here’s Why I Hate New Year’s Resolutions – Healthline
Hofseth Biocare ASA: Last day of subscription period in the Subsequent Offering – GlobeNewswire
Posted: Published on December 18th, 2020
December 18, 2020 02:00 ET | Source: Hofseth Biocare ASA NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL Reference is made to the stock exchange announcement by Hofseth BioCare ASA (the "Company") on 4 December 2020 regarding the approval by the Financial Supervisory Authority of Norway of the Company's prospectus dated 3 December 2020 (the "Prospectus") prepared in connection with inter alia, a subsequent offering of new shares in the Company (the "Offer Shares"). The subscription period in the Subsequent Offering will end today and Subscription Rights that are not used to subscribe for Offer Shares before 16:30 hours (CET) today, on 18 December 2020, will have no value and will lapse without compensation to the holder Continue reading
Posted in Ulcerative Colitis
Comments Off on Hofseth Biocare ASA: Last day of subscription period in the Subsequent Offering – GlobeNewswire
Immunic, Inc. Added to NASDAQ Biotechnology Index – BioSpace
Posted: Published on December 18th, 2020
NEW YORK, Dec. Continue reading
Posted in Ulcerative Colitis
Comments Off on Immunic, Inc. Added to NASDAQ Biotechnology Index – BioSpace
Group of friends walk 10km to raise 1000 for Crohns and Colitis UK – Bridgwater Mercury
Posted: Published on December 18th, 2020
A GROUP of friends who all suffer from Crohns or Ulcerative Colitis took part in a 10km walk last month to raise funds for charity. Charlotte, Toni, Alice and Mike took on the challenge on October 25 with support from their family and friends. The team of four raised 1,085 for Crohns and Colitis UK - a charity which is dedicated to helping people with Crohn's disease, ulcerative colitis, and other forms of inflammatory bowel disease to live a better quality of life and ultimately find a cure. Continue reading
Posted in Ulcerative Colitis
Comments Off on Group of friends walk 10km to raise 1000 for Crohns and Colitis UK – Bridgwater Mercury
Abivax completes recruitment of ABX464 Phase 2b induction study in ulcerative colitis – PharmiWeb.com
Posted: Published on December 7th, 2020
DGAP-News: ABIVAX / Key word(s): Study 30.11.2020 / 19:00 The issuer is solely responsible for the content of this announcement. Abivax completes recruitment of ABX464 Phase 2b induction study in ulcerative colitis PARIS, November 30, 2020 - 7:00 p.m. (CET) - Abivax (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, announced today the completion of recruitment for its Phase 2b induction study for the lead candidate ABX464 for the treatment of patients with moderate-to-severe ulcerative colitis. Continue reading
Posted in Ulcerative Colitis
Comments Off on Abivax completes recruitment of ABX464 Phase 2b induction study in ulcerative colitis – PharmiWeb.com
Bacainn Therapeutics Reports Positive Topline Results from Phase 1 Study of BT051, a Novel Therapeutic Approach to Treat Inflammatory Diseases Such As…
Posted: Published on December 7th, 2020
CONCORD, Mass.--(BUSINESS WIRE)--Bacainn Therapeutics, Inc., a Company developing novel therapies to address uncontrolled inflammation, today announced the successful completion of the companys Phase 1, first-in-human clinical trial of BT051, a novel, orally administered, gut-selective inhibitor of migration and activation of neutrophils. During active flares of ulcerative colitis, neutrophils migrate into the submucosa and lumen of the colon where they contribute to tissue damage by releasing a cocktail of destructive enzymes, DNA, histones and pro-inflammatory mediators. Continue reading
Posted in Ulcerative Colitis
Comments Off on Bacainn Therapeutics Reports Positive Topline Results from Phase 1 Study of BT051, a Novel Therapeutic Approach to Treat Inflammatory Diseases Such As…
Opinion: Open Restrooms in Maryland for People With Chronic Conditions – Josh Kurtz
Posted: Published on December 7th, 2020
I once lived with a secret that devastated my life. My secret transformed my successful career into endless days of fear and evasion.I was terrified of the 20-minute commute to my office. I depended upon ruses and excuses to explain why I suddenly vanished from meetings Continue reading
Posted in Ulcerative Colitis
Comments Off on Opinion: Open Restrooms in Maryland for People With Chronic Conditions – Josh Kurtz